Bookmark Saya

DOAJ Open Access 2022

Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer

Lianxi Song Liang Zeng Huan Yan Qinqin Xu Qing Xia +7 lainnya
Lihat Sumber DOI

Abstrak

Song, Zeng, Yan et al. validate the E1L3N monoclonal antibody for the detection of PD-L1 in NSCLC samples. The authors show that PD-L1 scores assessed with E1L3N are concordant with the 22C3 assay and are associated with response to first-line pembrolizumab monotherapy.

Topik & Kata Kunci

Medicine

Penulis (12)

L

Lianxi Song

L

Liang Zeng

H

Huan Yan

Q

Qinqin Xu

Q

Qing Xia

J

Jian Lei

X

Xiaoyan Chen

X

Xiaoping Hu

Z

Zhan Wang

H

Hong Liu

N

Nong Yang

Y

Yongchang Zhang

Format Sitasi

APA MLA BibTeX
Song, L., Zeng, L., Yan, H., Xu, Q., Xia, Q., Lei, J. et al. (2022). Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer. https://doi.org/10.1038/s43856-022-00206-4

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →
Lihat di Sumber doi.org/10.1038/s43856-022-00206-4
Informasi Jurnal
Tahun Terbit
2022
Sumber Database
DOAJ
DOI
10.1038/s43856-022-00206-4
Akses
Open Access ✓